Literature DB >> 2096488

Increased heparin cofactor II levels in women taking oral contraceptives.

P Toulon1, J M Bardin, N Blumenfeld.   

Abstract

Heparin cofactor II (HCII) is a thrombin inhibitor present in human plasma whose activity is enhanced by heparin. HCII exhibits important homologies with antithrombin III, the main heparin-enhanced thrombin inhibitor. Cases of recurrent thromboembolism have been recently reported in patients with HCII deficiency. Since the use of oral contraceptives (OC) is associated with an increased risk of thrombosis, the study of the plasma levels of HCII was undertaken in women taking contraceptive pills. Plasma HCII levels were found significantly higher in 62 women taking low-estrogen content OC (1.20 +/- 0.28 U/ml) than in 62 age matched women not taking OC (0.94 +/- 0.16 U/ml) or in 62 men (0.96 +/- 0.19 U/ml). Significant correlations between HCII and fibrinogen levels were reported in the three groups. From the pooled data of the two control groups (men and women not taking OC), the normal range for plasma HCII levels was defined to be between 0.60 and 1.30 U/ml (mean +/- 2 SD). Two cases of low HCII levels (less than 0.60 U/ml) were found in the control groups, but none in the group of women taking OC. It is concluded that the use of oral contraceptives is associated with a rise in HCII levels and that the screening for HCII deficiency has to be performed at distance of any OC therapy.

Entities:  

Keywords:  Biology; Blood Coagulation Effects; Contraception; Contraceptive Methods--side effects; Control Groups; Demographic Factors; Examinations And Diagnoses; Family Planning; Hematological Effects; Hemic System--changes; Laboratory Examinations And Diagnoses; Oral Contraceptives--side effects; Physiology; Population; Population Characteristics; Research Methodology; Risk Factors

Mesh:

Substances:

Year:  1990        PMID: 2096488

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  1 in total

1.  Functional Characterization of Antithrombin Mutations by Monitoring of Thrombin Inhibition Kinetics.

Authors:  Sara Reda; Jens Müller; Anna Pavlova; Behnaz Pezeshkpoor; Johannes Oldenburg; Bernd Pötzsch; Heiko Rühl
Journal:  Int J Mol Sci       Date:  2021-02-20       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.